Submission + - California to become first state to sell cheap insulin 3
Nicholas Grayhame writes: KTLA reports: California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell an affordable version of the drug to residents, Gov. Gavin Newsom announced Thursday.
Beginning Jan. 1, 2026, insulin glargine pens, a long-acting insulin analog used in the management of diabetes, will be available to consumers for no more than $55 for a five-pack of 3 mL pens, averaging $11 per pen.
... California previously launched a similar initiative for naloxone, the opioid overdose reversal medication.
Newsom has signed related measures to curb drug costs, including legislation capping insulin copays at $35 per month and tightening regulations on pharmacy benefit managers.
Beginning Jan. 1, 2026, insulin glargine pens, a long-acting insulin analog used in the management of diabetes, will be available to consumers for no more than $55 for a five-pack of 3 mL pens, averaging $11 per pen.
Newsom has signed related measures to curb drug costs, including legislation capping insulin copays at $35 per month and tightening regulations on pharmacy benefit managers.
Why this is is important AND a good idea. (Score:2)
Diabetics have two different problems.
1) Too little sugar in their blood.
2) Too much sugar in their blood.
Too little sugar literally means you starve to death in minutes. It does not matter if you have 200 lbs of fat on your body, if the fat is not releasing the sugar into your blood, then your heart, lung, brains have nothing to eat and you die of starvation - even if you look over weight.
Solution is to monitor your blood sugar (either constantly with a Continuous Glucose Monitoring device inserted in your
Thank you very much (Score:1)
That was a very informative post.
more (Score:1)
More from gov.ca.gov [ca.gov]:
Through an agreement secured by Civica Rx — a nonprofit generic drug manufacturer — with Biocon Biologics, Californians will have access to an interchangeable biosimilar insulin glargine pen offered under the CalRx brand and pricing. ...
Insulin glargine is a long-acting insulin analog used in the management of diabetes. The CalRx insulin glargine pens are interchangeable with Lantus®, ensuring seamless substitution for patients, and will be available to California pharmacies for $45 and to consumers at a suggested retail price of no more than $55 per five-pack of 3 mL pens—a substantial reduction from current retail market prices. ...
The insulin glargine pen agreement with Biocon Biologics complements Civica Rx’s broader insulin development strategy. Civica Rx continues its ongoing efforts to independently produce interchangeable biosimilar versions of insulin glargine and rapid-acting insulin under the CalRx label, further solidifying a reliable and affordable insulin supply for Californians. ...